Navigation Links
Wyeth to Present at the Merrill Lynch 2008 Global Pharmaceutical, Biotechnology and Medical Device Conference
Date:2/4/2008

MADISON, N.J., Feb. 4 /PRNewswire-FirstCall/ -- Wyeth (NYSE: WYE) announced today that it will present at the Merrill Lynch 2008 Global Pharmaceutical, Biotechnology and Medical Device Conference on Thursday, February 7, 2008 at 10:20 a.m. Eastern Time. Presenting for Wyeth will be Geno Germano, President, U.S. Pharmaceuticals & Women's Health Care, Wyeth Pharmaceuticals.

Wyeth's presentation will be webcast live for investors at http://www.wyeth.com and available for replay following the conference.

Wyeth is one of the world's largest research-driven pharmaceutical and health care products companies. It is a leader in the discovery, development, manufacturing, and marketing of pharmaceuticals, vaccines, biotechnology products, and non-prescription medicines that improve the quality of life for people worldwide. The Company's major divisions include Wyeth Pharmaceuticals, Wyeth Consumer Healthcare, and Fort Dodge Animal Health.

The statements in this press release that are not historical facts are forward-looking statements based on current expectations of future events that involve risks and uncertainties including, without limitation, risks associated with the inherent uncertainty of the timing and success of pharmaceutical research, product development, manufacturing, commercialization, economic conditions including interest and currency exchange rate fluctuations, changes in generally accepted accounting principles, the impact of competitive or generic products, trade buying patterns, wars or terrorist acts, product liability and other types of lawsuits, the impact of legislation and regulatory compliance and obtaining reimbursement, favorable drug pricing, access and other approvals, environmental liabilities, and patent, and other risks and uncertainties, including those detailed from time to time in the Company's periodic reports, including current reports on Form 8-K, quarterly reports on Form 10-Q and the annual report on Form 10-K, filed with the Securities and Exchange Commission. Actual results may vary materially from the forward-looking statements. The Company assumes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE Wyeth
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Wyeth Reports Earnings Results for the 2007 Fourth Quarter and Full Year
2. Wyeth Consumer Healthcare Supports U.S. Food and Drug Administration Decision for Over-the-Counter Cough and Cold Medications in Children under Two Years of Age
3. Wyeth Will Pursue Claim for Damages Resulting From Teva Pharmaceuticals Launch of Generic Pantoprazole in Violation of PROTONIX Patent
4. Pfizer, Genentech, Amgen, Bayer, Wyeth, Abbott, Merck and Additional Leading Pharmaceutical Companies Participating During ExL Pharmas Fall Line Up!
5. Wyeth Provides Update on Regulatory Review of Viviant (bazedoxifene)
6. Raven biotechnologies, inc. and Wyeth Pharmaceuticals Extend Evaluation Period of Selected Raven Antibodies
7. Wyeth Declares Preferred Stock Dividend
8. Wyeth Announces Election of New Principal Corporate Officer
9. Wyeth Pharmaceuticals Acquires Haptogen Ltd. to Boost Biotechnology Drug Discovery
10. Wyeth Announces $5 Billion Share Repurchase Program; Declares Increase in Common Stock Dividend
11. Wyeth Sets Webcast and Conference Call for 2007 Third Quarter Earnings
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... , March 29, 2017  Halozyme Therapeutics, Inc. ... and drug-delivery therapies, today announced that an Oncologic ... Drug Administration voted 11 to 0 that the ... injection was favorable for patients in the proposed ... and chronic lymphocytic leukemia. The FDA action date ...
(Date:3/29/2017)... (PRWEB) , ... March 29, 2017 , ... Bactana Animal ... hormones in the world’s food supply through enhancement of the gut microbiota, today announced ... included Connecticut Innovations , New York-based Sustainable Income Capital Management, LLC and a ...
(Date:3/29/2017)... 2017 /PRNewswire/ -  GeneNews Limited (TSX:GEN) ("GeneNews" or the ... new risk stratification test for breast cancer, via its ... ("IDL"). BreastSentry incorporates a blood-based biomarker test with a sophisticated ... developing breast cancer.   ... BreastSentry measures the fasting plasma levels of ...
(Date:3/28/2017)... ... March 28, 2017 , ... NetDimensions announced today that ... enhance training plan management for consistent implementation of standards and regulatory requirements across ... Group to help improve and streamline their training and employee development programs, which ...
Breaking Biology Technology:
(Date:3/7/2017)...   HireVue , the leading provider of video ... best talent, faster, today announced the additions of ... Diana Kucer as Chief Marketing Officer (CMO). ... poised to drive continued growth in the company,s new ... record bookings in 2017. "Companies worldwide turn ...
(Date:3/2/2017)... , March 2, 2017 Who risk ... lawsuits? Download the full report: https://www.reportbuyer.com/product/4313699/ ... THE FINGERPRINT SENSOR FIELD? Fingerprint sensors using capacitive ... The fingerprint sensor vendor Idex forecasts an increase of ... mobile devices and of the fingerprint sensor market between ...
(Date:2/28/2017)... News solutions for biometrics, bag drop and New ADA-compliant kiosk ... At PTE 2017 ... Materna will present its complete end-to-end passenger journey, from ... benefit for passengers. To accelerate the whole passenger handling process, ... to take passengers through the complete integrated process with a ...
Breaking Biology News(10 mins):